Clinical Trial Update: T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) [Phase 3]

View source ↗

Summary

Phase 3 trial of T-Guard (Xenikos) for steroid-refractory acute graft-versus-host disease was terminated; results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• T-Guard

Snippet

Sponsor: Xenikos | Conditions: Steroid-Refractory Acute Graft Versus Host Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-08-04